This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Par Pharmaceutical Companies, Inc.

Robbins Geller Rudman & Dowd LLP (“Robbins Geller”) ( today announced that a class action has been commenced in the United States District Court for the District of New Jersey on behalf of all persons who held shares of the common stock of Par Pharmaceutical Companies, Inc. (“Par Pharma”) (NYSE:PRX) as of August 2, 2012, against TPG Capital, L.P., Sky Growth Holding Corporation, and Sky Growth Acquisition Corporation (collectively, “TPG”), and Par Pharma and its Board of Directors (the “Board”) for violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the “1934 Act”) in connection with the proposed sale of Par Pharma to TPG, pursuant to which Par Pharma shareholders will receive $50.00 in cash for each share of common stock they own.

If you wish to serve as lead plaintiff, you must move the Court no later than 60 days from today. If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff’s counsel, Mark S. Reich of Robbins Geller at 631/367-7100, or via email at If you are a member of this class, you can view a copy of the complaint as filed or join this class action online at Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

The complaint charges Par Pharma and its Board and TPG with violations of the 1934 Act. Par Pharma is a U.S.-based specialty pharmaceutical company that develops, manufactures and markets high-barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals.

The complaint alleges that defendants failed to disclose material information in a proxy statement filed with the SEC and publicly disseminated in connection with the proposed sale of Par Pharma to TPG. According to the complaint, the proxy statement was materially false and misleading because it made numerous material omissions about the process leading up to the agreement between Par Pharma and TPG and the work performed by Par Pharma’s financial advisor, J.P. Morgan Securities LLC, which was retained by Par Pharma to evaluate the fairness of TPG’s offer.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs